Lipoxin B4
Based on 1 Customer Validation
Lipoxin B4 (LXB4) is a structurally distinct product of arachidonic acid metabolism. Lipoxin B4 reduces leukocyte infiltration and mucus secretion in the nasal mucosa and decreases mast cell and eosinophil degranulation in the upper airway. Lipoxin B4 decreases airway inflammation, mucus metaplasia and hyper- responsiveness in the lower airway. Lipoxin B4 shows mucosal protective actions and has the potential for the research of allergic inflammation in the upper and lower airways.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.2%
- CAS No.: 98049-69-5
- Formule: C20H32O5
- Masse moléculaire:352.47
-
Stockage:
Solution, -20°C, 2 years
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-113509
Lipoxin A4Anti-inflammatory Agent -
HY-113509B
15(R)-Lipoxin A4Specialized Pro-resolving Mediator -
HY-126722
Lipoxin A4 methyl esterLipoxin Analog -
HY-113492
5(S)15(S)-DiHETEPlatelet Aggregation Inhibitor -
HY-100450
BML-111Lipoxin A4 Receptor Agonist -
HY-130239
14(S)-HDHADHA Oxygenation Product -
HY-113884B
(S)-Coriolic acidPPARγ Activator/Mitochondrial Dysfunction Inducer -
HY-115381
Lipoxin A5Endogenous Metabolite -
HY-130429
14,15-Leukotriene C4Leukotrienes -
HY-113483
20-Carboxy-Leukotriene B4LTB4 Metabolite -
HY-113490
15-KETE -
HY-118149
9(S)-HpODE
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
Description
IC50 & Target
|
Human Endogenous Metabolite |
Chemical Information
-
CAS No. 98049-69-5
-
Appearance Liquid
-
Masse moléculaire 352.47
-
Formule C20H32O5
-
Color Colorless to light yellow
-
SMILES
CCCCC[C@H](O)[C@H](O)/C=C/C=C/C=C\C=C\[C@@H](O)CCCC(O)=O
-
Synonyms
LXB4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Solution, -20°C, 2 years
Protocole
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
-
Fiche technique (262 KB)
-
SDS (545 KB)
- English - EN (545 KB)
- Français - FR (545 KB)
- Deutsch - DE (545 KB)
- Norwegian - NO (545 KB)
- Español - ES (545 KB)
- Swedish - SV (545 KB)
- Italian - IT (545 KB)
- Korean - KR (545 KB)
- Portuguese - PT (545 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lipoxin B4 Related Classifications
HY-116953 Related Classifications
Powered by Bioz